Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR
10.1007/s11684-020-0795-4
- Author:
Wenjie ZHU
1
;
Binghe XU
2
Author Information
1. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing, 100021, China.
2. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing, 100021, China. bhxu@hotmail.com.
- Publication Type:Review
- Keywords:
HR+/HER2− advanced breast cancer;
endocrine-resistant;
meta-analysis;
randomized clinical trials;
targeted therapy
- MeSH:
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Breast Neoplasms/drug therapy*;
Hormones;
Humans;
Randomized Controlled Trials as Topic;
Receptor, ErbB-2;
Receptors, Estrogen
- From:
Frontiers of Medicine
2021;15(2):208-220
- CountryChina
- Language:English
-
Abstract:
New targeted therapies have been developed to overcome resistance to endocrine therapy (ET) and improve the outcome of HR
